Drugs / Pyridoxal 5'-Phosphate
Pyridoxal 5'-Phosphate
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03738943 | Feb 2019 → Jun 2021 | — | Colorado State University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05366933 | Aug 2022 → Jul 2027 expected | optic nerve disorder | National Aeronautics and Space Administration (NASA) | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01281878 | Dec 2010 → Sep 2012 | primary hyperoxaluria type 1 | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT00917293 | May 2009 → Aug 2012 | tardive dyskinesia | Medicure | Terminated | No outcome recorded |
| Phase 2 | NCT00157729 | Aug 2004 → Jul 2005 | hypertensive disorder, metabolic syndrome X, type 2 diabetes mellitus | Medicure | Completed | No outcome recorded |
| Phase 2 | NCT00157716 | Apr 2004 → Oct 2005 | coronary artery disorder, myocardial ischemia | Medicure | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04706013 | Feb 2024 → Nov 2026 expected | inborn disorder of pyridoxine metabolism | Medicure | Recruiting | No outcome recorded |
| Phase 3 | NCT00402506 | Nov 2006 → Sep 2007 | myocardial ischemia | Medicure | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04762316 | Jan 2019 → Dec 2025 | uterine corpus leiomyoma | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07469462 | May → Nov 2026 expected | anxiety, depressive disorder | University of Reading | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyridoxal-5-phosphate | “Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency” NCT04706013 ↗7“100mg Vitamin B6 as pyridoxal-5-phosphate, daily with food” NCT07469462 ↗ |
| Known as | MC-1 | “(MC-1) Pyridoxal-5'-phosphate” NCT00157716 ↗ |
| Known as | pyridoxal-phosphate | “Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg...” NCT01281878 ↗4“Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight.” NCT01281878 ↗ “Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin” NCT05366933 ↗ “Pregnenolone 60mg & Pyridoxal Phosphate 20mg & Dydrogesterone 10mg & Impatien balsamina extract 100 mg” NCT04762316 ↗ |
| Known as | Vitamin B6 | “100mg Vitamin B6 as pyridoxal-5-phosphate, daily with food” NCT07469462 ↗ |
| Action | Inhibit | “the purpose of this study is to determine whether Vitamin B6 or PLP can inhibit vasodilation” NCT03738943 ↗ |
| Modality | Other / unclassified | “daily nutraceutical supplement containing bioactive B vitamins” NCT05366933 ↗ |
| Route | Oral | “Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.” NCT00917293 ↗ |